Centermed Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Centermed Sp. z o.o. in Lublin, clinical research in cardiology focuses on major cardiovascular diseases, especially atherosclerotic cardiovascular disease and elevated lipoprotein(a). These studies are designed to test new ways to reduce serious heart-related events and improve long-term outcomes for patients at higher risk.
- Studying treatments for atherosclerotic cardiovascular disease and elevated lipoprotein(a)
- Evaluating prevention of heart attack, stroke, and coronary complications
- Assessing the effectiveness of new therapies for reducing cardiovascular risk
These trials reflect a strong interest in better managing high-risk heart disease through innovative treatment strategies and improved protection against major cardiovascular events.
Nutritional and Metabolic Diseases
Research at this site also covers nutritional and metabolic diseases, with studies involving obesity, overweight, and type 2 diabetes mellitus. The main goal is to explore therapies that may help with weight management, metabolic control, and related health complications.
- Testing new treatments for obesity and overweight
- Examining therapies for type 2 diabetes mellitus in people with high cardiovascular risk
- Exploring options that may improve both metabolic health and overall disease control
These investigations connect weight-related conditions with broader metabolic and heart health concerns, showing a clear focus on practical treatment benefits for patients.
Obesity and Knee Osteoarthritis
One area of clinical trial activity looks at obesity and knee osteoarthritis, studying whether treatment can support weight reduction while also addressing joint-related symptoms. This research aims to improve both metabolic health and mobility in people affected by these overlapping conditions.
- Investigating treatment effects in obesity and overweight
- Including participants with knee osteoarthritis
- Seeking better symptom control and functional improvement
The work highlights how managing excess weight may also benefit joint health, making this an important topic for patients with combined metabolic and musculoskeletal concerns.
Metabolic and Cardiovascular Risk Reduction
Another stream of research at the site examines therapies intended to lower cardiovascular risk in people with type 2 diabetes mellitus. These studies compare treatment options to understand which approaches may better prevent major heart and vascular events while supporting diabetes care.
- Studying treatments in type 2 diabetes mellitus
- Evaluating protection against major cardiovascular events
- Comparing therapies to identify more effective long-term care strategies
This research area is especially relevant for patients whose diabetes is accompanied by a higher chance of serious heart complications, and it supports more personalized treatment decisions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centermed Sp. z o.o.
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA) | AstraZeneca AB | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2024-03-14 | 2024-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.